NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

IDYA

Ideaya Biosciences Inc

Jun 30 • 04:00PM ET

21.02

Dollar change -0.35
Percentage change -1.64	%

Healthcare • Biotechnology • USA • NASD

Peers: EXEL INCY NBIX BPMC ARGX FATE YMAB NERV GOSS ENTA

| Held by: VTI IWM XBI VXF IWN IBB SCHA VTWO VHT AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.59	Insider Own	10.05%	Shs Outstand	87.57M	Perf Week	-1.87%
Market Cap	1.84B	Forward P/E	-	EPS next Y	-2.99	Insider Trans	0.00%	Shs Float	78.78M	Perf Month	4.84%
Enterprise Value	1.17B	PEG	-	EPS next Q	-0.79	Inst Own	106.24%	Short Float	14.40%	Perf Quarter	23.28%
Income	-307.08M	P/S	263.00	EPS this Y	3.86%	Inst Trans	7.96%	Short Ratio	7.71	Perf Half Y	-16.92%
Sales	7.00M	P/B	1.80	EPS next Y	7.38%	ROA	-29.78%	Short Interest	11.34M	Perf YTD	-18.21%
Book/sh	11.70	P/C	2.66	EPS next 5Y	13.88%	ROE	-31.34%	52W High	44.42 -52.68%	Perf Year	-39.74%
Cash/sh	7.91	P/FCF	-	EPS past 3/5Y	-33.53% -0.01%	ROIC	-29.25%	52W Low	13.45 56.28%	Perf 3Y	52.10%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-36.96% -	Gross Margin	44.50%	Volatility	4.47% 4.55%	Perf 5Y	47.72%
Dividend TTM	-	EV/Sales	167.78	EPS Y/Y TTM	-79.25%	Oper. Margin	-5147.81%	ATR (14)	0.99	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.92	Sales Y/Y TTM	-54.85%	Profit Margin	-4386.90%	RSI (14)	49.54	Recom	1.14
Dividend Gr. 3/5Y	- -	Current Ratio	13.92	EPS Q/Q	-55.04%	SMA20	-3.41%	Beta	0.03	Target Price	51.08
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	5.10%	Rel Volume	0.59	Prev Close	21.37
Employees	131	LT Debt/Eq	0.03	Earnings	May 06 BMO	SMA200	-11.60%	Avg Volume	1.47M	Price	21.02
IPO	May 23, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-24.04% -100.00%	Trades		Volume	866,729	Change	-1.64%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-26-25	Initiated	Wells Fargo	Overweight	$44
Nov-18-24	Initiated	Stephens	Overweight	$51
Nov-05-24	Downgrade	Leerink Partners	Outperform → Market Perform	$27
Oct-24-24	Initiated	UBS	Buy	$50
Oct-15-24	Initiated	Cantor Fitzgerald	Overweight
Jul-08-24	Initiated	Mizuho	Outperform	$50
Mar-08-24	Initiated	BTIG Research	Buy	$55
Aug-08-23	Initiated	SVB Securities	Outperform	$33
May-24-23	Initiated	Goldman	Buy	$32
Apr-24-23	Upgrade	Stifel	Hold → Buy	$18 → $24
Mar-23-23	Initiated	Berenberg	Buy	$26
Feb-28-23	Initiated	RBC Capital Mkts	Outperform	$25
Dec-28-22	Initiated	CapitalOne	Overweight	$29
Oct-27-22	Initiated	Citigroup	Buy	$26
Aug-15-22	Downgrade	Stifel	Buy → Hold	$16 → $13
Jul-18-22	Resumed	Oppenheimer	Outperform	$25
Mar-10-22	Upgrade	Stifel	Hold → Buy	$27 → $20
Sep-23-21	Initiated	Stifel	Hold	$27
Jun-04-21	Resumed	Robert W. Baird	Outperform	$28
Mar-11-21	Initiated	Guggenheim	Buy	$32

Show Previous Ratings

Jun-27-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-26-25 09:49AM	General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls (The Fly)
Jun-02-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events (PR Newswire) +6.69%
May-30-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-06-25 06:05AM	IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update (PR Newswire) -13.29%
06:00AM	Loading…
06:00AM	IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors (PR Newswire)
May-05-25 07:51AM	Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential (Insider Monkey)
Apr-28-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events (PR Newswire)
Apr-27-25 09:22AM	Immunocore Holdings: A Name On My Watch List (Seeking Alpha)
Apr-25-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-16-25 08:52AM	Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later (Seeking Alpha)
Apr-14-25 06:00AM	IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma (PR Newswire)
Apr-10-25 06:00AM	IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy Combination in MTAP-Deletion Urothelial Cancer (PR Newswire)
Apr-02-25 11:49AM	Hospitals Experience FOMO In Adopting Delcath's PHP Treatment (Seeking Alpha) +10.70%
11:12AM	Why Ideaya Biosciences Is Down Despite Many Positives (Seeking Alpha)
06:00AM	Loading…
Apr-01-25 06:00AM	IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events (PR Newswire) -9.83%
Mar-31-25 06:00AM	IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma (PR Newswire)
Mar-28-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Mar-26-25 06:00AM	IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor (PR Newswire)
Mar-20-25 09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-05-25 02:45PM	IDEAYA Biosciences, Inc. (IDYA) Partners with ATTMOS for AI-Driven Drug Discovery Platform (Insider Monkey)
Mar-03-25 06:00AM	IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets (PR Newswire) -7.00%
Feb-28-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Feb-14-25 09:35AM	Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA) (Zacks)
Feb-13-25 07:15AM	IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss (Zacks) -5.42%
06:05AM	IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (PR Newswire)
06:00AM	IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy and IDE397 in MTAP-Deletion NSCLC (PR Newswire)
Feb-10-25 12:00PM	All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy (Zacks)
06:00AM	IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer (PR Newswire)
Jan-31-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
05:07PM	Loading…
Jan-30-25 05:07PM	Here's Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025 (Insider Monkey)
Jan-27-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events (PR Newswire)
Jan-12-25 12:00PM	IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance (PR Newswire)
Dec-29-24 06:00AM	IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors (PR Newswire)
Dec-27-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-17-24 06:00AM	IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma (PR Newswire)
Dec-16-24 06:00AM	IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers (PR Newswire)
Dec-11-24 06:00AM	IDEAYA Announces Agenda for Investor RandD Day Webcast on December 16, 2024 (PR Newswire)
06:00AM	IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 (PR Newswire)
Dec-10-24 06:00AM	IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA (pembrolizumab) in Patients with Endometrial Cancer (PR Newswire)
Dec-09-24 06:00AM	IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor (PR Newswire)
Dec-06-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.38%
Dec-02-24 06:00AM	IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events (PR Newswire)
Nov-29-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-22-24 07:33AM	Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Nov-18-24 06:00AM	IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer (PR Newswire)
Nov-12-24 06:00AM	IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day (PR Newswire)
Nov-11-24 06:00AM	IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen (PR Newswire)
06:00AM	Biocytogen Announces IDEAYAs Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise (Business Wire)
Nov-07-24 09:55AM	Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know (Zacks)
Nov-04-24 08:30AM	IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
08:30AM	/C O R R E C T I O N -- IDEAYA Biosciences, Inc./ (PR Newswire)
Nov-01-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-29-24 10:01AM	Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline (Zacks)
Oct-28-24 06:00AM	IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors (PR Newswire)
Oct-25-24 06:00AM	IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024 (PR Newswire)
Oct-04-24 06:00AM	IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium (PR Newswire)
Sep-27-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-24-24 08:13AM	IDEAYAs rare cancer drug shows promise as company lays out Phase III plans (Clinical Trials Arena) -7.00%
Sep-23-24 06:00AM	IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma (PR Newswire)
Sep-22-24 09:00AM	IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024 (PR Newswire)
Sep-18-24 06:00AM	IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel (PR Newswire)
Aug-30-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-26-24 06:00AM	IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (PR Newswire)
Aug-23-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-06-24 01:54PM	IDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q2 2024 (InvestorPlace)
06:00AM	IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Aug-01-24 10:01AM	IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-31-24 06:00AM	IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen (PR Newswire)
06:00AM	Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program (Business Wire)
Jul-29-24 06:00AM	IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event (PR Newswire)
Jul-23-24 09:55AM	How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97% (Zacks)
Jul-11-24 04:05PM	IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire) +6.16%
Jul-09-24 10:26PM	IDEAYA Announces Pricing of Public Offering (PR Newswire)
04:08PM	IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire)
01:49PM	IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data (Zacks)
06:54AM	Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength? (Zacks)
06:52AM	IDEAYA Biosciences reports positive data from Phase II trial of cancer treatment (Clinical Trials Arena)
Jul-08-24 04:15PM	Why Ideaya Biosciences Just Made Its Most Bullish Move Since March (Investor's Business Daily) +15.32%
12:57PM	Top Stock Movers Now: Intel, Corning, SolarEdge, and More (Investopedia)
12:08PM	IDEAYA Biosciences Soars on Cancer Drug Study Results (Investopedia)
06:00AM	IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer (PR Newswire)
Jul-05-24 04:05PM	IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024 (PR Newswire)
Jun-28-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-26-24 07:13AM	IDEAYA Biosciences initiates subject dosing in Phase I bladder cancer trial (Clinical Trials Arena)
Jun-25-24 06:00AM	IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer (PR Newswire)
Jun-24-24 06:00AM	IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors (PR Newswire)
Jun-03-24 06:00AM	IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study (PR Newswire) +6.40%
May-31-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-29-24 06:00AM	IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events (PR Newswire)
May-28-24 06:00AM	IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development (PR Newswire)
May-23-24 09:21PM	IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma (PR Newswire) -7.08%
09:21PM	/C O R R E C T I O N -- IDEAYA Biosciences, Inc./ (PR Newswire)
May-16-24 05:57PM	Ideaya Biosciences Insider Sold Shares Worth $7,397,291, According to a Recent SEC Filing (MT Newswires)
May-08-24 08:47AM	Oppenheimer Adjusts IDEAYA Biosciences Price Target to $53 From $50, Maintains Outperform Rating (MT Newswires)
May-07-24 01:54PM	IDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q1 2024 (InvestorPlace)
10:23AM	IDEAYA Biosciences Shares Fall After Q1 Loss (MT Newswires)
07:35AM	IDEAYA Biosciences Inc (IDYA) Reports Q1 2024 Earnings: Financial and Strategic Developments (GuruFocus.com)
06:00AM	IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
May-01-24 06:00AM	IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event (PR Newswire)

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. It focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hata Yujiro S	President and CEO	Feb 18 '25	Option Exercise	19.52	12,808	250,012	690,695	Feb 19 06:00 AM
Jason Throne	Former Officer	Aug 26 '24	Proposed Sale	40.22	75,000	3,016,500		Aug 26 05:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IDYA

Ideaya Biosciences Inc

Upgrade your FINVIZ experience